US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.88

+0.19150.49%

Post-market: 38.85-0.0315-0.08%19:30 EDT

Volume:49.35K

Turnover:1.92M

Market Cap:354.60M

PE:- -

High:38.94

Open:38.78

Low:38.66

Close:38.69

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:0.65

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Press Release: Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

Oriole Seals Senala JV with Managem as US$2m Drill Campaign Nears

Press Release: Oryzon Raises EUR12 Million and Signs a Financing Agreement with Cofides to Strengthen Its Balance Sheet and Accelerate Its Clinical Programs

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

New Partner Emerges for RAS Inhibitors in Treating the "King of Cancers"

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

Groundbreaking Cancer Treatment Doubles Survival in Pancreatic Cancer, Cutting Death Risk by 60%

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ORR/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.8815,"timestamp":1787601600000,"preClose":38.69,"halted":0,"volume":49353,"hourTrading":{"tag":"盘后","latestPrice":38.85,"preClose":38.8815,"latestTime":"19:30 EDT","volume":11,"amount":427.8905,"timestamp":1787614207188,"change":-0.0315,"changeRate":-0.00081,"amplitude":0},"delay":0,"changeRate":0.0049495993796848,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Closed","change":0.1915,"latestTime":"08-24 16:00:00 EDT","open":38.78,"high":38.935,"low":38.66,"amount":1915913.762742,"amplitude":0.007108,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":38.69,"sharesOutstanding":12900000,"nav":38.62,"aum":352214400,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.85,"preClose":38.8815,"latestTime":"19:30 EDT","volume":11,"amount":427.8905,"timestamp":1787614207188,"change":-0.0315,"changeRate":-0.00081,"amplitude":0},"volumeRatio":0.650059,"impliedVol":0.1458,"impliedVolPercentile":0.5316},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.650059,"shares":9120000,"dividePrice":0,"high":38.935,"amplitude":0.007108,"preClose":38.69,"low":38.66,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.8815,"eps":0,"divideRate":0,"volume":49353,"delay":0,"ttmEps":0,"open":38.78,"prevYearClose":34.16,"prevWeekClose":38.69,"prevMonthClose":38.79,"prevQuarterClose":36.32,"fiveDayClose":38.09,"twentyDayClose":37.26,"sixtyDayClose":36.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649675228","title":"Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2649675228","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649675228?lang=en_us&edition=fundamental","pubTime":"2026-07-07 01:59","pubTimestamp":1783360740,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322680/0/en/Genmab-Announces-TEPKINLY-epcoritamab-in-Combination-with-Lenalidomide-and-Rituximab-is-Approved-by-the-European-Commission-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-L.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","APHP","BK4201","CR","BK4161","LU2065731478.USD","BK4006","EC","IE00B19Z4B17.USD","IE0031619046.USD","BK4187","PYZ","ORR","BK4108","EPV","LU0963586101.USD","BK4195","PFS","BK4211","CRS","XAR","IE00B66KJ199.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649062991","title":"Press Release: Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2649062991","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649062991?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:00","pubTimestamp":1783339200,"startTime":"0","endTime":"0","summary":"NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\"Corbus\" or the \"Company\"), a clinical-stage company focused on developing promising new therapi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NETL","BK4022","ORR","BK4139","R","BK4231","ADC","BK4080","CRBP","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649092645","title":"Oriole Seals Senala JV with Managem as US$2m Drill Campaign Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2649092645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649092645?lang=en_us&edition=fundamental","pubTime":"2026-07-06 14:18","pubTimestamp":1783318721,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Oriole Resources PLC ( ($GB:ORR) ). Oriole Resources PLC has finalized a joint venture agreement with Managem s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oriole-seals-senala-jv-with-managem-as-us2m-drill-campaign-nears?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oriole-seals-senala-jv-with-managem-as-us2m-drill-campaign-nears?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648545938","title":"Press Release: Oryzon Raises EUR12 Million and Signs a Financing Agreement with Cofides to Strengthen Its Balance Sheet and Accelerate Its Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2648545938","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648545938?lang=en_us&edition=fundamental","pubTime":"2026-07-01 21:08","pubTimestamp":1782911280,"startTime":"0","endTime":"0","summary":"-- Priced at EUR2.70 per share, representing a 14.15% discount on the. five-day VWAP and a 12.68% discount to the June 30 closing price. -- The transaction has been structured as a capital increase without the. -- Proceeds will be used to advance the Company's clinical development. -- Cover general and administrative expenses and financial obligations.Dr. Carlos Buesa, Chief Executive Officer of Oryzon, said: \"This funding comes at a particularly important time for Oryzon and strengthens our ability to execute our clinical strategy with greater confidence. The progress of our acute myeloid leukemia program is attracting increasing attention across the international oncology ecosystem, including among leading experts, pharmaceutical companies, and specialized investors. With this support, we gain financial flexibility to accelerate our priority programs while continuing to explore strategic opportunities that can maximize the value of our platform.\"Agreement with the Social Impact Fund ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4090","CNS","ORR","AAQC","BK4135","BK4156","CMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646870966","title":"MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646870966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646870966?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:08","pubTimestamp":1782389280,"startTime":"0","endTime":"0","summary":"Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June  25, 2026  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317503/0/en/MAIA-Biotechnology-Completes-International-Enrollment-in-Part-C-of-Phase-2-THIO-101-Expansion-Trial-in-Third-Line-Non-Small-Cell-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","L","MAIA","CPI","BK4588","BK4585","BK4107","LU2487616109.SGD","LU0053666078.USD","BK4139","LU0210528500.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646484290","title":"HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2646484290","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646484290?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:00","pubTimestamp":1782345600,"startTime":"0","endTime":"0","summary":"— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317235/0/en/HUTCHMED-Highlights-Pivotal-Phase-II-Data-for-Fanregratinib-in-Intrahepatic-Cholangiocarcinoma-Presented-at-ESMO-Gastrointestinal-Cancers-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","ORR","BK1588","BK1191","BK4195","BK4211","PFS","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643548277","title":"Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76","url":"https://stock-news.laohu8.com/highlight/detail?id=2643548277","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643548277?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:30","pubTimestamp":1781519400,"startTime":"0","endTime":"0","summary":"29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy Cytokine Release Syndrome (“CRS”)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3311621/0/en/Context-Therapeutics-Announces-Positive-Interim-Efficacy-and-Safety-Results-from-Ongoing-Phase-1-Clinical-Trial-for-CTIM-76.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ORR","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228204","title":"Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228204","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228204?lang=en_us&edition=fundamental","pubTime":"2026-06-15 07:30","pubTimestamp":1781479800,"startTime":"0","endTime":"0","summary":"Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ROCKVILLE, Md. and SUZHOU, Ch","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311475/0/en/Ascentage-Pharma-Presents-Multiple-Clinical-Updates-at-EHA2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4211","CSF","BK4139","ORR","AAPG","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643246367","title":"Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2643246367","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643246367?lang=en_us&edition=fundamental","pubTime":"2026-06-14 15:15","pubTimestamp":1781421300,"startTime":"0","endTime":"0","summary":"Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 studySingle infusion of LB2501 generated dose-dependent","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311435/0/en/Legend-Biotech-Establishes-Clinical-Proof-of-Concept-for-LB2501-a-Potential-First-in-Class-In-Vivo-CD19-CD20-Dual-Targeting-CAR-T-in-Relapsed-Refractory-B-Cell-Non-Hodgkin-Lymphoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4022","ORR","XBI","BK4588","BK4187","CAR","IE00B66KJ199.SGD","BK4230","LU2065731478.USD","IRR","BK4505","BK4139","IE00B19Z4B17.USD","LEGN","LU0963586101.USD","CRS","BK4006","BK4581","IE00B7SZL793.SGD","IE0031619046.USD","BK4585","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643217815","title":"Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643217815","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643217815?lang=en_us&edition=fundamental","pubTime":"2026-06-14 00:45","pubTimestamp":1781369100,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly di","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/13/3311409/0/en/Genmab-Announces-Epcoritamab-Monotherapy-and-Epcoritamab-Based-Combination-Regimens-Demonstrate-High-Response-Rates-in-Elderly-Patients-with-Newly-Diagnosed-Diffuse-Large-B-Cell-Ly.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4161","CRS","BK4187","PFS","IE00B66KJ199.SGD","BK4006","IE00B7SZL793.SGD","LU2065731478.USD","ORR","BK4211","IE0031619046.USD","IE00B19Z4B17.USD","LU0963586101.USD","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642238199","title":"Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating  Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642238199","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642238199?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:45","pubTimestamp":1781189100,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lena","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310630/0/en/Genmab-Presents-EPCORE-FL-1-Subgroup-Data-Demonstrating-Consistent-Efficacy-and-Safety-Results-for-Epcoritamab-in-Combination-with-Rituximab-and-Lenalidomide-R2-Across-Relapsed-or-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4161","PFS","ORR","BK4203","BK4211","HR","BK4225","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282822","title":"Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282822","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282822?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179200,"startTime":"0","endTime":"0","summary":"-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-nave patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case stu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310377/0/en/Caribou-Biosciences-Reports-Dose-Escalation-Durability-Data-for-CB-011-at-the-2026-European-Hematology-Association-EHA-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417517546.SGD","LU0963586101.USD","BK4187","BK4107","CRBU","LU0256863811.USD","IE00B19Z4B17.USD","CRS","LU0314106906.USD","BK4139","IE00B66KJ199.SGD","LU1506573853.SGD","BK4599","IE00B7SZL793.SGD","BK4022","ORR","BK4539","IE0031619046.USD","CAR","ALT","BK4006","LD","BK4559","BK4230","LU0868494617.USD","EPV","BK4585","LU2065731478.USD","LU1878469433.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289420","title":"Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289420","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289420?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:03","pubTimestamp":1781175780,"startTime":"0","endTime":"0","summary":"–Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – –Ph 1 trial of revumenib with int","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310342/0/en/Syndax-Showcases-Revuforj-revumenib-Clinical-Activity-in-Multiple-Acute-Leukemia-Subtypes-and-Settings-at-EHA-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","ORR","BK4107","ECG","CR","BK4533","BK4161","LU2355687059.USD","LU1559883803.SGD","BK4585","ALL","SAVE","HSCT","BK4008","BK4129","BK4588","LU1699723380.USD","BK4500","LU0985320562.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289288","title":"C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289288","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289288?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175600,"startTime":"0","endTime":"0","summary":"At the 100 g Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310320/0/en/C4-Therapeutics-Presents-Phase-1-Data-at-European-Hematology-Association-EHA-2026-Congress-Highlighting-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-for-Multiple-Myelo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1261432733.SGD","EPV","BK4139","BK4213","IE00B19Z3B42.SGD","BK4161","CI","BK4196","BK4585","IE00B19Z3581.USD","BK4588","LU1059921491.USD","LU0289739699.SGD","LU0868494617.USD","IE0002270589.USD","PR","LU0058720904.USD","CCCC","IE00BSNM7G36.USD","ORR","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642401957","title":"Cellectis Presents Final Phase 1 Results of Lasme-cel and  Preliminary Results on Eti-cel at EHA 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2642401957","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642401957?lang=en_us&edition=fundamental","pubTime":"2026-06-11 14:40","pubTimestamp":1781160000,"startTime":"0","endTime":"0","summary":"NEW YORK, June  11, 2026  (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310207/0/en/Cellectis-Presents-Final-Phase-1-Results-of-Lasme-cel-and-Preliminary-Results-on-Eti-cel-at-EHA-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4231","IE0031619046.USD","BK4161","BK4006","CRS","CLLS","CR","LU2065731478.USD","ADC","BK4139","BK4230","HSCT","IE00B66KJ199.SGD","BK4022","IE00B19Z4B17.USD","IE00B7SZL793.SGD","BK4187","BK4080","CAR","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642209429","title":"MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642209429","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642209429?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:15","pubTimestamp":1781097300,"startTime":"0","endTime":"0","summary":"Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $7","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309785/0/en/MAIA-Biotechnology-Activates-and-Opens-Enrollment-at-Second-U-S-Clinical-Site-for-International-Phase-2-THIO-101-Expansion-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","L","CPI","BK4139","LU2487616109.SGD","LU0053666078.USD","LU0210528500.USD","MAIA","BK4585","BK4081","EMA","BK4107","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109356337","title":"New Partner Emerges for RAS Inhibitors in Treating the \"King of Cancers\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1109356337","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109356337?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:21","pubTimestamp":1781000505,"startTime":"0","endTime":"0","summary":"Pancreatic cancer is often referred to as the \"king of cancers.\" This label reflects the harsh reality long faced by patients: rapid disease progression, subtle early symptoms, frequent late-stage...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2357305700.SGD","LU2360107325.USD","LU1861214812.USD","LU1548497426.USD","ORR","IE00BZ199S13.USD","LU1854103824.USD","BK4588","BK4211","IE00BFMHRM44.USD","LU1861219969.SGD","PFS","ON","LU1854104046.USD","LU1978683503.SGD","IE00BD6J9T35.USD","LU1720051017.SGD","LU2298322129.HKD","BK4195","BK4605","BK4512","LU1861215975.USD","LU1861220033.SGD","LU0348723411.USD","BK4141","LU0124384867.USD","LU1720051108.HKD","BK4585","LU0724618433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640184320","title":"Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2640184320","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640184320?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:05","pubTimestamp":1780517100,"startTime":"0","endTime":"0","summary":"First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy  SAN CARLOS, Calif., June  03, 2026  (GLOBE NE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3306385/0/en/Iovance-s-Amtagvi-lifileucel-Granted-Approval-for-the-Treatment-of-Advanced-Melanoma-in-Australia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4505","IE00B19Z4B17.USD","TIL","IE00B66KJ199.SGD","ORR","BK4157","AEIS","LU1815336091.USD","LU0757428866.USD","IE00B7SZL793.SGD","IE0031619046.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119298317","title":"Groundbreaking Cancer Treatment Doubles Survival in Pancreatic Cancer, Cutting Death Risk by 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119298317","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119298317?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:13","pubTimestamp":1780492387,"startTime":"0","endTime":"0","summary":"A historic breakthrough has been achieved in the global treatment of pancreatic cancer.The innovative drug Daraxonrasib, developed by RedMed, has demonstrated in its latest Phase III clinical trial...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFMHRM44.USD","BK4585","ON","BK4195","LU1854103824.USD","LU2298322129.HKD","BK4141","LU0724618433.USD","IE00BZ199S13.USD","LU1861220033.SGD","BK4588","BK4605","LU1720051108.HKD","LU1720051017.SGD","LU1548497426.USD","ORR","LU2357305700.SGD","IE00BD6J9T35.USD","LU2360107325.USD","LU1861214812.USD","LU0348723411.USD","BK4512","LU1861215975.USD","LU0124384867.USD","BK4211","PFS","LU1854104046.USD","LU1861219969.SGD","LU1978683503.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640978848","title":"ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2640978848","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640978848?lang=en_us&edition=fundamental","pubTime":"2026-06-03 10:47","pubTimestamp":1780454820,"startTime":"0","endTime":"0","summary":"BEIJING, June  02, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced toda","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305756/0/en/ASCO-2026-Updated-Data-from-an-Oral-Presentation-of-InnoCare-s-Novel-BCL2-Inhibitor-Mesutoclax-in-MDS-and-AML-Released.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1721428933.USD","BK4533","IE00BFXG0V08.USD","ORR","BK4585","BK4567","BK4161","IE00BYQQ9H92.USD","LU2211817866.USD","CR","IE00B5TLWC47.USD","LU0347712357.USD","BK4588","BK4121","BK4548","LU2413666699.HKD","MTD","LU1093756168.USD","LU2413666426.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":133,"code":"91000000","status":"200"}]}}